-
公开(公告)号:US08269017B2
公开(公告)日:2012-09-18
申请号:US12883883
申请日:2010-09-16
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: C07D261/02 , A61K31/42
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
摘要翻译: 本发明涉及结构式(I)的化合物或其药学上可接受的盐,溶剂化物,包合物和前药,其中R a,R b和R 2在本文中定义。 这些化合物抑制微管蛋白聚合和/或靶向脉管系统,并且可用于治疗增殖性疾病如癌症。
-
公开(公告)号:US20110059893A1
公开(公告)日:2011-03-10
申请号:US12883883
申请日:2010-09-16
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: A61K38/06 , A61K31/675 , A61K31/501 , A61K31/4725 , A61K31/4709 , A61K31/4439 , A61K31/42 , C07K5/08 , C07F9/09 , C07D261/08 , C07D413/10 , C07D413/04 , A61K31/422 , A61P35/00 , A61P7/00 , A61P27/02
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
摘要翻译: 本发明涉及结构式(I)的化合物或其药学上可接受的盐,溶剂化物,包合物和前药,其中R a,R b和R 2在本文中定义。 这些化合物抑制微管蛋白聚合和/或靶向脉管系统,并且可用于治疗增殖性疾病如癌症。
-
公开(公告)号:US08598366B2
公开(公告)日:2013-12-03
申请号:US13558886
申请日:2012-07-26
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: C07D261/02
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
-
公开(公告)号:US08329899B2
公开(公告)日:2012-12-11
申请号:US13026981
申请日:2011-02-14
申请人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
发明人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
IPC分类号: C07D473/00 , C07D401/14 , C07D277/62 , C07D231/00 , C07D487/12 , C07D403/14
CPC分类号: C07D231/20 , C07D231/18 , C07D231/38 , C07D403/04
摘要: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
摘要翻译: 式(I)化合物,包含式(I)化合物的药物组合物和抑制细胞中Hsp90的方法,治疗或预防哺乳动物中的增殖病症并治疗哺乳动物的癌症,其包括给予式(I)化合物至 患者或细胞。 变量R5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R18。 环A是除了R3之外任选进一步被一个或多个取代基取代的芳基或杂芳基。 取代基R 3在本文中定义。
-
公开(公告)号:US20110144332A1
公开(公告)日:2011-06-16
申请号:US13026981
申请日:2011-02-14
申请人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
发明人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
IPC分类号: C07D473/00 , C07D403/10 , C07D405/10 , C07D417/10 , C07D401/04
CPC分类号: C07D231/20 , C07D231/18 , C07D231/38 , C07D403/04
摘要: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
摘要翻译: 式(I)化合物,包含式(I)化合物的药物组合物和抑制细胞中Hsp90的方法,治疗或预防哺乳动物中的增殖病症并治疗哺乳动物的癌症,其包括给予式(I)化合物至 患者或细胞。 变量R5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R18。 环A是除了R3之外任选进一步被一个或多个取代基取代的芳基或杂芳基。 取代基R 3在本文中定义。
-
公开(公告)号:US07608635B2
公开(公告)日:2009-10-27
申请号:US11502346
申请日:2006-08-10
申请人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
发明人: Weiwen Ying , Shijie Zhang , Zhenjian Du , Kevin Foley
IPC分类号: A61K31/415 , C07D231/10
CPC分类号: C07D231/20 , C07D231/18 , C07D231/38 , C07D403/04
摘要: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
摘要翻译: 式(I)化合物,包含式(I)化合物的药物组合物和抑制细胞中Hsp90的方法,治疗或预防哺乳动物中的增殖病症并治疗哺乳动物的癌症,其包括给予式(I)化合物至 患者或细胞。 变量R5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R18。 环A是除了R3之外任选进一步被一个或多个取代基取代的芳基或杂芳基。 取代基R 3在本文中定义。
-
公开(公告)号:US07884094B2
公开(公告)日:2011-02-08
申请号:US11355922
申请日:2006-02-16
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: A61K31/33 , C07D261/02
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
-
公开(公告)号:US20060217389A1
公开(公告)日:2006-09-28
申请号:US11355922
申请日:2006-02-16
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: A61K31/506 , A61K31/501 , A61K31/497 , A61K31/4709 , A61K31/4439 , A61K31/426 , A61K31/42
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
摘要翻译: 本发明涉及结构式(I)的化合物或其药学上可接受的盐,溶剂化物,包合物和前药,其中R a,R b, SUB> 2 SUB>在本文中定义。 这些化合物抑制微管蛋白聚合和/或靶向脉管系统,并且可用于治疗增殖性疾病如癌症。
-
公开(公告)号:US08629285B2
公开(公告)日:2014-01-14
申请号:US11502347
申请日:2006-08-10
申请人: Weiwen Ying , Zhenjian Du , Kevin Foley
发明人: Weiwen Ying , Zhenjian Du , Kevin Foley
IPC分类号: A61K31/52 , A61K31/4178 , A61K31/4188 , A61K31/437 , C07D473/00 , C07D401/04 , C07D403/04 , C07D417/04
CPC分类号: A61K31/4164 , A61K31/4178 , A61K31/4184 , A61K31/428 , A61K31/4709 , A61K31/52 , A61K31/5377 , A61K31/675 , C07D233/70 , C07D233/84 , C07D233/88 , C07D403/02 , C07D403/04 , C07D403/10 , C07F9/6506
摘要: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
摘要翻译: 式(I)化合物,包含式(I)化合物的药物组合物和抑制细胞中Hsp90的方法,治疗或预防哺乳动物中的增殖病症并治疗哺乳动物的癌症,其包括给予式(I)化合物至 患者或细胞变量R5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R18。 环A是除了R3之外任选进一步被一个或多个取代基取代的芳基或杂芳基。 取代基R 3在本文中定义。
-
公开(公告)号:US20120289483A1
公开(公告)日:2012-11-15
申请号:US13558886
申请日:2012-07-26
申请人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
发明人: Lijun Sun , Christopher Borella , Hao Li , Jun Jiang , Shoujun Chen , Keizo Koya , Takayo Inoue , Zhenjian Du , Kevin Foley , Yaming Wu , Mei Zhang , Weiwen Ying
IPC分类号: A61K31/42 , C07D261/08 , C07F9/653 , C07D413/04 , A61P35/00 , A61K31/4439 , A61K31/4725 , A61K31/4709 , A61K31/422 , A61K31/675 , C07D413/10
CPC分类号: C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/675 , A61K45/06 , C07D261/08 , C07D413/04 , C07D413/10 , C07F9/653
摘要: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
-
-
-
-
-
-
-
-
-